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Abstract
Background: Purine nucleoside phosphorylase (PNP) 
deficiency has been recently introduced in the newborn 
screening program in Tuscany. In order to improve the 
PNP screening efficiency, we developed a 2nd tier test to 
quantify PNP primary markers deoxyguanosine (dGuo) 
and deoxyinosine (dIno).
Methods: Dried blood spots (DBS) samples were extracted 
with 200 μL of methanol and 100 μL of water (by two steps). 
Internal standards were added at a final concentration of 
10 μmol/L. After extraction, samples were analysed by 
LC-MS/MS. The chromatographic run was performed in 
gradient mode by using a Synergi Fusion column.
Results: The assay was linear over a concentration range 
of 0.05–50 μmol/L (R2 > 0.999) for dGuo and 0.5–50 μmol/L 
(R2 > 0.998) for dIno. Intra- and interassay imprecision 
(mean CVs) for dIno and dGuo ranged from 2.9% to 12%. 
Limit of quantitaion (LOQ) were found to be 0.05 μmol/L 
and 0.5 μmol/L for dGuo and dIno, respectively. The refer-
ence ranges, obtained by measuring dGuo and dIno con-
centrations on DBS, were close to zero for both biomarkers. 
Moreover, DBS samples from seven patients with confirmed 
PNP were retrospectively evaluated and correctly identified.
Conclusions: The LC-MS/MS method can reliably measure 
dIno and dGuo in DBS for the diagnosis of PNP. Validation 
data confirm the present method is characterised by good 
reproducibility, accuracy and imprecision for the quanti-
tation of dIno and dGuo. The assay also appears suitable 
for use in monitoring treatment of PNP patients.
Keywords: 2nd tier test; dried blood spot; newborn screen-
ing; purine nucleoside phosporilase; purine nucleoside 
phosphorylase deficiency; severe combined immunodefi-
ciency; tandem mass spectrometry.
Introduction
Purine nucleoside phosphorylase (PNP) deficiency 
represents approximately the 4% of severe combined 
immunodeficiencies (SCID) [1]. PNP is a key enzyme 
in the purine degradation and salvage pathway that 
catalyses phosphorilation of inosine-deoxyinosine and 
guanosine- deoxyguanosine to hypoxantine and guanine. 
Then, metabolites are converted to uric acid or back to 
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nucleotides through the salvage pathway [2]. The enzyme 
deficiency results in a particularly serious accumulation of 
all four metabolites but most of all deoxyinosine and deox-
yguanosine. The phosphorylation of deoxyguanosine leads 
to the formation of a lymphocyte toxic metabolite, the deox-
yguanosine triphosphate (dGTP) [3]. dGTP causes inhibi-
tion of ribonucleotide reductase and DNA synthesis [4]. As 
a result, uric acid levels should be low and PNP deficiency 
may be suspected in the presence of hypouricaemia. Never-
theless, recent cases described many patients with normal 
plasma levels of uric acid and then this marker should not 
be used in differential diagnosis of PNP deficiency [5, 6].
Typically PNP deficiency causes T-cell immunodefi-
ciency and for this reason patients suffer from recurrent 
infections of the respiratory tract, neurologic abnormali-
ties and autoimmunity [1, 5, 7–9].
Early detection of primary immunodeficiency is rec-
ognized as important for avoiding infectious complica-
tions that compromise outcomes [10].
Some newborn screening (NBS) programs evaluate 
T-cell receptor excision circle (TREC) and kappa-deleting 
recombination excision circle (KREC) levels on dried blood 
spots (DBSs) by quantitative real-time PCR. However, 
Azzari et  al. demonstrated that both, TREC and KREC 
quantitative analysis, might fail in identification of some 
forms of delayed or late-onset immunodeficiencies [11].
In 2011, we developed a method by tandem mass 
spectrometry (MS/MS) to include adenosine deaminase 
deficiency (ADA-SCID) in the NBS for inborn errors of 
metabolism [12, 13]. This inexpensive and sensitive proce-
dure, applied to NBS, allowed to identify an infant with 
ADA deficiency in pre-symptomatic stage of illness to 
prevent progression to severe complications [13].
Recently, we have also included PNP metabolites in 
the NBS panel demonstrating that MS/MS is able to iden-
tify PNP patients [14].
Since patients are characterized by a profile of ele-
vated metabolite levels (Guo, Ino, dGuo and dIno) the 
false-positive rate is very low. However, it is difficult to 
exclude possible contaminants in flow injection analysis 
used for NBS purposes and a 2nd tier test is an useful tool 
to avoid parental anxiety due to an unnecessary recall 
testing. The 2nd tier test is performed when first NBS 
result is positive in order to detect the disease marker by 
chromatographic separation coupled to MS/MS under the 
optimum operating condition [15].
In this work, we present a validated method able to 
detect and quantify the primary markers of PNP defi-
ciency (dGuo and dIno). It is not only suitable as 2nd tier 
test but also it is a rapid, noninvasive diagnostic test when 
a PNP deficiency is suspected.
Materials and methods
Chemicals and reagents
[2H2] 2′-deoxyguanosine monohydrate and [15N4]-deoxyinosine were 
purchased from Omicron Biochemicals (South Bend, IN, USA). Stock 
solutions of labelled standards were prepared at 10 mmol/L in HPLC 
grade water and stored at –20 °C. Working solutions were daily pre-
pared by dilution to a final concentration of 10 μmol/L from stock 
solutions.
dGuo and dIno reference standards to prepare calibration 
curve and quality controls (QC) were purchased from Sigma Aldrich 
(St. Louis, MO, USA).
All solvents were HPLC grade purity and were purchased from 
Sigma Aldrich (St. Louis, MO, USA). Blood was spotted on filter paper 
grade 903 (Whatman GmbH, Dasel, Germany).
Samples
Blood spot specimens were collected from 250 healthy controls 
(150 newborns and 100 adults) and anonymously analysed in order 
to establish reference ranges. We retrospectively analyzed stored 
DBS from seven patients with confirmed PNP deficiency. One of 
samples was collected from a newborn on 3rd day of life. All sam-
ples were  collected at time of diagnosis before any treatment has 
been started. Informed consent were obtained from patients before 
 sample  analysis.
All experiments were conducted in compliance with institu-
tional review board guidelines (regional pilot project protocol no. 
7949/2011). DBS were stored in sealed plastic bags at –20 °C until 
analysis.
Sample preparation
A 3.2 mm disk was punched from DBS and extracted with 200 μL of 
methanol containing 10 μmol/L of IS. A volume of 100 μL of water 
was added in a second step to prevent blood haemolysis and to facili-
tate purine extraction from paper. The mixture was incubated by 
a gentle shaking for 25 min at 37 °C. Samples were transferred to a 
clean micro-well plate and analysed.
Preparation of calibration standards and quality control 
(QC) samples
Calibration standards and QC samples were prepared by spotting 
25 μL of pooled whole blood on filter paper. After extraction, differ-
ent concentrations of dGuo and dIno were added to the extracts. QC 
samples for imprecision studies were prepared at 0.1 μmol/L (LQC), 
10 μmol/L (MQC), 25 μmol/L (HQC) for dGuo and at 1 μmol/L (LQC), 
10 μmol/L (MQC), 25 μmol/L (HQC) for dIno. For evaluation of the 
linearity the calibration curve was constructed at concentrations of 
0.1, 1, 5, 10, 12.5, 25, 50 μmol/L for dGuo and 0.5, 1, 5, 10, 12.5, 25, 
50 μmol/L for dIno. For the validation study QC samples and calibra-
tion standards were freshly prepared.
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LC-MS/MS
Analyses were performed using Infinity 1260 System (Agilent Tech-
nologies, Waldbronn, Germany), coupled with an API 4000 tri-
ple quadrupole mass spectrometer (AB Sciex, Toronto, Canada) 
equipped with a TurboV-Spray® source with the turbo gas tempera-
ture set at 425 °C. The source operates in positive ionization polar-
ity at a potential of +5500 V. Mass parameters are listed in Table 1. 
Each instrument module was fully controlled by the Analyst Software 
 (Version 1.5.2).
The chromatographic run was performed by using a Synergi 
Fusion column, 4 μm, 150 × 2 mm (Phenomenex, Torrance, CA, USA) 
at a flow rate of 250 μL/min; the eluate was flowed directly into the 
ESI source without splitting. The mobile phase, composed of a mix-
ture of 0.25% formic acid in water (A) and 0.1% formic acid in ace-
tonitrile (B), was applied in a gradient mode. The gradient started 
with 10% of solvent B for 0.1 min, ramped up to 35% in 4 min, then 
was increased to 80% in 0.1 min. After 1 min the initial condition was 
restored and held for 5 min. Injection volume was 3 μL. The analyte 
concentrations were calculated using the option Quantitate of the 
Analyst Software (AB Sciex, Toronto, Canada).
Method validation
This method was validated in terms of linearity, specifity, intra- and 
inter-day accuracy and imprecision.
The lower limit of quantitation (LLOQ) was determined 
 preparing a specific calibration curve in the range 0–1 μmol/L for 
both analytes; the residual standard deviation of the regression line 
and its slope were used to calculate LLOQ, according to ICH guide-
line [16].
The accuracy and imprecision were determined by the analysis 
of QC samples at three concentrations. Ten replicates of each level 
of QC samples were assayed in one run for the intraday accuracy 
and imprecision evaluation. For the interday experiment, three rep-
licates of each QC sample were analysed within ten different days. 
The intra- and interday imprecision and accuracy of the assay were 
expressed as percent coefficient of variation (CV) and percent bias 
values, respectively.
In order to evaluate the matrix effect on the ionization of the 
analytes, blank DBS samples were extracted and spiked at LQC, MQC 
and HQC concentrations for both analytes and compared to solvent 
samples spiked at the same concentrations. All samples contained 
10 μmol/L of IS.
Table 1: Summary of analytes and their MRM transitions and MS 
parameters. CXP and EP values were 22 V and 10 v, respectively, for 
all transitions.
Analytes  Q1, m/z  Q3, m/z  DP, V  CE, V
dGuo   268.2  152.1  40  18
dIno   253.2  137.1  30  13
dGuo IS   270.2  152.1  40  18
dIno IS   257.2  141.1  30  13
CXP, Collision exit potential; EP, entrance potential; DP, declustering 
potential; CE, collision energy.
Results and discussion
PNP deficiency results in accumulation of purines (Guo, 
Ino, dIno and dGuo), generated from DNA degradation. In 
particular, the deoxynucleoside accumulation are toxic to 
lymphocytes, leading to profound T cell-mediated immu-
nosuppression. Under normal physiological conditions, 
the deoxynucleosides, unlike Guo and Ino, are unde-
tectable (dGuo) or close to zero (dIno) on human whole 
blood because they are rapidly phosphorylated by PNP. 
This makes dGuo and dIno the best biomarker candidates 
to identify PNP deficiency by MS/MS (Figure 1) although 
increased levels of all the four purines were found in the 
samples from PNP patients retrospectively analysed [14].
Purine nucleoside phosphorylase is a cytoplas-
mic enzyme that is present in all mammalian cells. For 
this reason, QC samples cannot be prepared by directly 
adding purine reference standards to the whole blood 
due to the rapid enzymatic metabolism, as previously 
reported [13].
The chromatographic conditions were optimized in 
order to obtain a good resolution of peaks within shorter 
time. The resolutions of these compounds were compared 
with different reversed phase analytical columns and the 
Synergi Fusion column (4 μm, 150 × 2 mm) was selected 
since results showed that only this column could supply 
appropriate resolution and response. The choice of mobile 
phase is equally important. In this study, acetonitrile-
water was chosen because this combination gave the best 
resolution for the analytes. No carry over of peaks were 
observed at the retention time of dGuo and dIno. The chro-
matographic column showed robust performances even 
after a several hundreds of injections.
A calibration curve with low concentrations 
( < 1 μmol/L) was generated for dIno and dGuo to determine 
the LLOQ by using the following equation: LLOQ = 10 σ/S, 
where σ = residual standard deviation and S = the slope of 
the regression line. LLOQ were found to be 0.05 μmol/L 
and 0.5 μmol/L for dGuo and dIno respectively.
The method was linear from 0.05 to 50 μmol/L 
(R2 > 0.999) for dGuo and 0.5 to 50 μmol/L (R2 > 0.998) for 
dIno.
The mean intraday and interday CVs for the analytes 
of interest are reported in Table 2. These data confirm that 
the present method has proven to have good reproducibil-
ity, accuracy and imprecision for the quantisation of dIno 
and dGuo.
Matrix effect could affect the reproducibility from 
the analyte or the internal standard of the assay and was 
calculated comparing peak areas from spiked analytes in 
DBS extracted matrix versus pure standards prepared in 
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solvent. No matrix effect was observed in any of the three 
QC concentrations for both analytes.
Concentration levels to establish reference range 
on DBS from a healthy population resulted be undetect-
able for dGuo and less than the LLOQ ( < 0.5 μmol/L) for 
dIno. No significant differences were observed between 
newborn and adult ranges.
We previously reported a LC-MS/MS method to 
include PNP-SCID in expanded newborn screening panel. 
DBS samples from 9 patients with diagnosed PNP-SCID 
were retrospectively analysed by using LC/MS-MS analysis 
in the flow-injection mode (FIA) as reported by la Marca 
et al. [14]. Unfortunately, we had sufficient material only 
of 7 patients to carry out 2nd tier test, in order to verify the 
analytical sensibility of this test (positive results correctly 
identified by the method). All seven patients were con-
firmed as positives by 2nd tier test and the corresponding 
values were in the range of 0.14–0.32 μmol/L for dGuo and 
0.89–3.32 μmol/L for dIno (Table 3). No correlation was 
found between metabolites levels and genotype although 
this study was based on a limited number of patients.
The present test is of great importance not only to 
make diagnosis of PNP-SCID but also to achieve therapy 
monitoring in patients undergoing bone marrow trans-
plantation or enzyme replacement therapy. For this 
purpose, DBS but also matrices as urine and plasma can 
be used to evaluate purine concentrations in suspected or 
confirmed PNP-SCID patients.
Figure 1: Extracted ion chromatogram from a normal control and a PNP patient.
Table 2: Intra- and interday precision and accuracy of the assay.
Intraday (10 replicates)  
 
Interday (In triplicate for 10 days)
Expected concentration, 
 μmol/L
  Mean, μmol/L  SD  CV, %  Accuracy 
(% Bias)
Expected concentration, 
μmol/L
  Mean, μmol/L  SD  CV, %  Accuracy 
(% Bias)
Deoxyguanosine   Deoxyguanosine
 0.1   0.11  0.01  7.9  +10.0   0.1   0.11  0.01  5.19  +10.0
 10   10.09  0.66  6.5  +0.9   10   10.48  0.44  4.2  +4.8
 25   23.95  1.48  6.1  –4.2   25   24.09  1.02  4.22  –3.7
Deoxyinosine   Deoxyinosine
 1   0.98  0.12  12.0  –2.0   1   1.01  0.08  7.8  +0.6
 10   10.27  0.84  8.2  +2.7   10   10.30  0.30  2.9  +3.0
 25   24.50  0.84  3.4  –2.0   25   24.45  0.77  3.2  –2.2
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Conclusions
A critical limitation of the method for some validation 
parameters is represented by QC sample preparation. 
However, the aim of this work was the development of a 
method with a high specificity, thanks to the chromato-
graphic separation before mass spectrometry detection, 
able to reduce false positive rate in NBS test. The method 
was found to be accurate, precise and reproducible and 
could be used in routine determination of PNP-SCID 
metabolites.
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